In patients with neuronopathic MPS II, long-term idursulfase-IT was generally well tolerated; the safety and tolerability profile over 36 months of treatment is consistent with that reported in the 52-week phase 2/3 trial [14]. This evidence concerns the gene IDS and mucopolysaccharidosis type 2.